Robert W. Baird Upgrade Pieris Pharmaceuticals Inc. [PIRS]. What else is Wall St. saying?

Pieris Pharmaceuticals Inc. [NASDAQ: PIRS] gained 13.26% on the last trading session, reaching $3.16 price per share at the time.

Pieris Pharmaceuticals Inc. represents 55.21 million in outstanding shares, while the company has a total market value of $169.00 million with the latest information. PIRS stock price has been found in the range of $2.80 to $3.31.

If compared to the average trading volume of 420.40K shares, PIRS reached a trading volume of 5197855 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Pieris Pharmaceuticals Inc. [PIRS]:

Robert W. Baird have made an estimate for Pieris Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 13, 2020. The new note on the price target was released on July 30, 2019, representing the official price target for Pieris Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $5, while Robert W. Baird analysts kept a Outperform rating on PIRS stock.

The Average True Range (ATR) for Pieris Pharmaceuticals Inc. is set at 0.23, with the Price to Sales ratio for PIRS stock in the period of the last 12 months amounting to 3.31. The Price to Book ratio for the last quarter was 3.51, with the Price to Cash per share for the same quarter was set at 1.62.

Trading performance analysis for PIRS stock

Pieris Pharmaceuticals Inc. [PIRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.49. With this latest performance, PIRS shares gained by 7.48% in over the last four-week period, additionally sinking by -21.00% over the last 6 months – not to mention a drop of -36.03% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PIRS stock in for the last two-week period is set at 57.29, with the RSI for the last a single of trading hit 62.79, and the three-weeks RSI is set at 53.97 for Pieris Pharmaceuticals Inc. [PIRS]. The present Moving Average for the last 50 days of trading for this stock 3.08, while it was recorded at 2.85 for the last single week of trading, and 3.16 for the last 200 days.

Pieris Pharmaceuticals Inc. [PIRS]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Pieris Pharmaceuticals Inc. [PIRS] shares currently have an operating margin of -58.68. Pieris Pharmaceuticals Inc.’s Net Margin is presently recorded at -55.03.

Return on Total Capital for PIRS is now -50.52, given the latest momentum, and Return on Invested Capital for the company is -47.71. Return on Equity for this stock declined to -55.80, with Return on Assets sitting at -18.04. When it comes to the capital structure of this company, Pieris Pharmaceuticals Inc. [PIRS] has a Total Debt to Total Equity ratio set at 31.58. Additionally, PIRS Total Debt to Total Capital is recorded at 24.00, with Total Debt to Total Assets ending up at 11.49. Long-Term Debt to Equity for the company is recorded at 30.15, with the Long-Term Debt to Total Capital now at 22.92.

Reflecting on the efficiency of the workforce at the company, Pieris Pharmaceuticals Inc. [PIRS] managed to generate an average of -$200,543 per employee. Receivables Turnover for the company is 9.76 with a Total Asset Turnover recorded at a value of 0.33.Pieris Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.80.

Pieris Pharmaceuticals Inc. [PIRS]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Pieris Pharmaceuticals Inc. posted -0.05/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 78.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PIRS.

An analysis of insider ownership at Pieris Pharmaceuticals Inc. [PIRS]

There are presently around $120 million, or 75.00% of PIRS stock, in the hands of institutional investors. The top three institutional holders of PIRS stocks are: BVF INC/IL with ownership of 5,872,762, which is approximately 9.773% of the company’s market cap and around 0.22% of the total institutional ownership; AQUILO CAPITAL MANAGEMENT, LLC, holding 5,575,530 shares of the stock with an approximate value of $17.62 million in PIRS stocks shares; and BLACKROCK INC., currently with $10.61 million in PIRS stock with ownership of nearly -1.397% of the company’s market capitalization.

Positions in Pieris Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 39 institutional holders increased their position in Pieris Pharmaceuticals Inc. [NASDAQ:PIRS] by around 7,706,503 shares. Additionally, 54 investors decreased positions by around 5,303,391 shares, while 22 investors held positions by with 25,035,775 shares. The mentioned changes placed institutional holdings at 38,045,669 shares, according to the latest SEC report filing. PIRS stock had 10 new institutional investments in for a total of 3,450,933 shares, while 22 institutional investors sold positions of 914,977 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam